Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Retained Earnings: 2016-2025

Historic Retained Earnings for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to -$1.3 billion.

  • Rhythm Pharmaceuticals' Retained Earnings fell 17.30% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 17.30%. This contributed to the annual value of -$1.2 billion for FY2024, which is 29.13% down from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Retained Earnings is -$1.3 billion, which was down 0.34% from -$1.3 billion recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Retained Earnings registered a high of -$415.6 million during Q1 2021, and its lowest value of -$1.3 billion during Q3 2025.
  • Its 3-year average for Retained Earnings is -$1.0 billion, with a median of -$1.1 billion in 2024.
  • Data for Rhythm Pharmaceuticals' Retained Earnings shows a maximum YoY plummeted of 39.97% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Retained Earnings stood at -$528.9 million in 2021, then plummeted by 34.24% to -$710.1 million in 2022, then decreased by 26.01% to -$894.7 million in 2023, then fell by 29.13% to -$1.2 billion in 2024, then dropped by 17.30% to -$1.3 billion in 2025.
  • Its last three reported values are -$1.3 billion in Q3 2025, -$1.3 billion for Q2 2025, and -$1.2 billion during Q1 2025.